Nonclinical precedent Request an invite

Enjaymo: how was the first human dose set?

sutimlimab · Complement C1s
First-in-human starting dose
Not stated in public reviews
Why it's blank

The public FDA and EMA reviews of Enjaymo don't say how the first human dose was chosen. That rationale is in the IND, which is confidential, so it is missing for most approved products.

How it's usually set for monoclonal antibodies outside oncology

Find the highest dose with no adverse effects (NOAEL) in each animal species, convert it to a human equivalent dose, usually by body surface area, pick the most appropriate species, then divide by a safety factor (default 10) to get the maximum recommended starting dose.

“In general, one should consider using a safety factor of at least 10. The MRSD should be obtained by dividing the HED by the safety factor.”
✓ VerifiedFDA 2005: Estimating the Maximum Safe Starting Dose in Initial Clinical…, p. 7Source ↗
This product's starting point

NOAEL / key findings: NOAEL 180 mg/kg/week (highest dose) in repeat-dose monkey study; no adverse findings despite near-complete classical complement inhibition (FDA pharmacology/toxicology review, p. 40)

Full method, every step sourced →

NOAEL / key findings
NOAEL 180 mg/kg/week (highest dose) in repeat-dose monkey study; no adverse findings despite near-complete classical complement inhibition
“The no observed adverse effect level (NOAEL) in the repeat-dose toxicity study was 180 mg/kg weekly in male and female monkeys.”
✓ VerifiedFDA pharmacology/toxicology review, p. 40Source ↗

Same question, other monoclonal antibodies

Anthim

obiltoxaximab · B. anthracis PA
Single-dose clinical escalation supported by monkey AUC margin: 10 mg/kg AUC ~50,000 µg·hr/mL vs human AUC 10,000 at 114 mg

Cinqair

reslizumab · IL-5
Phase 1 single-dose escalation in severe asthma at 0.03 to 1.0 mg/kg; derivation of starting dose not described

Danyelza

naxitamab · GD2
Initial trials based on prior clinical data with the murine parent antibody, not on toxicology data with naxitamab

Imaavy

nipocalimab · FcRn
First-in-human SAD in healthy volunteers started at 0.3 mg/kg IV, escalating to 60 mg/kg; derivation not stated

Rituxan

rituximab · CD20
Based on monkey pilot study relating multiple-dose rituximab exposure to B-cell depletion

Sarclisa

isatuximab · CD38
MABEL and in vitro receptor occupancy: 0.0001 mg/kg, about 10% predicted CD38 occupancy in B and T cells

Actemra

tocilizumab · IL-6R
Not stated in public reviews

Adakveo

crizanlizumab · P-selectin
Not stated in public reviews

Adbry

tralokinumab · IL-13
Not stated in public reviews

Aduhelm

aducanumab · Aggregated amyloid-β
Not stated in public reviews

Aimovig

erenumab · CGRP receptor
Not stated in public reviews

Ajovy

fremanezumab · CGRP
Not stated in public reviews

Alhemo

concizumab · TFPI
Not stated in public reviews

Andembry

garadacimab · Factor XIIa
Not stated in public reviews

Arzerra

ofatumumab · CD20
Not stated in public reviews

Avastin

bevacizumab · VEGF-A
Not stated in public reviews

Bavencio

avelumab · PD-L1
Not stated in public reviews

Benlysta

belimumab · BLyS (BAFF)
Not stated in public reviews

Beovu

brolucizumab · VEGF-A
Not stated in public reviews

Beyfortus

nirsevimab · RSV F protein
Not stated in public reviews

Bimzelx

bimekizumab · IL-17A/IL-17F
Not stated in public reviews

Briumvi

ublituximab · CD20
Not stated in public reviews

Cablivi

caplacizumab · von Willebrand factor (A1 domain)
Not stated in public reviews

Campath

alemtuzumab · CD52
Not stated in public reviews

Cimzia

certolizumab pegol · TNF-α
Not stated in public reviews

Cosentyx

secukinumab · IL-17A
Not stated in public reviews

Crysvita

burosumab · FGF23
Not stated in public reviews

Cyramza

ramucirumab · VEGFR2
Not stated in public reviews

Darzalex

daratumumab · CD38
Not stated in public reviews

Dupixent

dupilumab · IL-4Ra
Not stated in public reviews

Ebanga

ansuvimab · Zaire ebolavirus glycoprotein
Not stated in public reviews

Ebglyss

lebrikizumab · IL-13
Not stated in public reviews

Emgality

galcanezumab · CGRP
Not stated in public reviews

Empliciti

elotuzumab · SLAMF7
Not stated in public reviews

Enflonsia

clesrovimab · RSV F protein (site IV)
Not stated in public reviews

Enspryng

satralizumab · IL-6R
Not stated in public reviews

Entyvio

vedolizumab · α4β7-integrin
Not stated in public reviews

Erbitux

cetuximab · EGFR
Not stated in public reviews

Evenity

romosozumab · Sclerostin
Not stated in public reviews

Evkeeza

evinacumab · ANGPTL3
Not stated in public reviews

Exdensur

depemokimab · IL-5
Not stated in public reviews

Fasenra

benralizumab · IL-5Rα
Not stated in public reviews

Gamifant

emapalumab · IFN-γ
Not stated in public reviews

Gazyva

obinutuzumab · CD20
Not stated in public reviews

Herceptin

trastuzumab · HER2
Not stated in public reviews

Humira

adalimumab · TNF-α
Not stated in public reviews

Hympavzi

marstacimab · TFPI
Not stated in public reviews

Ilaris

canakinumab · IL-1β
Not stated in public reviews

Ilumya

tildrakizumab · IL-23 p19
Not stated in public reviews

Imfinzi

durvalumab · PD-L1
Not stated in public reviews

Imjudo

tremelimumab · CTLA-4
Not stated in public reviews

Jemperli

dostarlimab · PD-1
Not stated in public reviews

Kevzara

sarilumab · IL-6R
Not stated in public reviews

Keytruda

pembrolizumab · PD-1
Not stated in public reviews

Kisunla

donanemab · Amyloid-β (N3pG)
Not stated in public reviews

Lartruvo

olaratumab · PDGFRα
Not stated in public reviews

Leqembi

lecanemab · Amyloid-β protofibrils
Not stated in public reviews

Libtayo

cemiplimab · PD-1
Not stated in public reviews

Loqtorzi

toripalimab · PD-1
Not stated in public reviews

Lucentis

ranibizumab · VEGF-A
Not stated in public reviews

Margenza

margetuximab · HER2
Not stated in public reviews

Monjuvi

tafasitamab · CD19
Not stated in public reviews

Nemluvio

nemolizumab · IL-31RA
Not stated in public reviews

Niktimvo

axatilimab · CSF-1R
Not stated in public reviews

Nucala

mepolizumab · IL-5
Not stated in public reviews

Ocrevus

ocrelizumab · CD20
Not stated in public reviews

Omvoh

mirikizumab · IL-23 p19
Not stated in public reviews

Opdivo

nivolumab · PD-1
Not stated in public reviews

Pasatru

garetosmab · Activin A
Not stated in public reviews

Penpulimab

penpulimab · PD-1
Not stated in public reviews

Perjeta

pertuzumab · HER2
Not stated in public reviews

Piasky

crovalimab · Complement C5
Not stated in public reviews

Portrazza

necitumumab · EGFR
Not stated in public reviews

Poteligeo

mogamulizumab · CCR4
Not stated in public reviews

Praluent

alirocumab · PCSK9
Not stated in public reviews

Praxbind

idarucizumab · Dabigatran
Not stated in public reviews

Prolia

denosumab · RANKL
Not stated in public reviews

Raxibacumab

raxibacumab · B. anthracis protective antigen
Not stated in public reviews

Remicade

infliximab · TNF-α
Not stated in public reviews

Repatha

evolocumab · PCSK9
Not stated in public reviews

Rystiggo

rozanolixizumab · FcRn
Not stated in public reviews

Saphnelo

anifrolumab · IFNAR1
Not stated in public reviews

Siliq

brodalumab · IL-17RA
Not stated in public reviews

Simponi

golimumab · TNF-α
Not stated in public reviews

Simulect

basiliximab · IL-2Rα (CD25)
Not stated in public reviews

Skyrizi

risankizumab · IL-23 p19
Not stated in public reviews

Soliris

eculizumab · Complement C5
Not stated in public reviews

Spevigo

spesolimab · IL-36R
Not stated in public reviews

Stelara

ustekinumab · IL-12/23 p40
Not stated in public reviews

Sylvant

siltuximab · IL-6
Not stated in public reviews

Synagis

palivizumab · RSV F protein
Not stated in public reviews

Takhzyro

lanadelumab · Plasma kallikrein
Not stated in public reviews

Taltz

ixekizumab · IL-17A
Not stated in public reviews

Tecentriq

atezolizumab · PD-L1
Not stated in public reviews

Tepezza

teprotumumab · IGF-1R
Not stated in public reviews

Tevimbra

tislelizumab · PD-1
Not stated in public reviews

Tezspire

tezepelumab · TSLP
Not stated in public reviews

Tremfya

guselkumab · IL-23 p19
Not stated in public reviews

Trogarzo

ibalizumab · CD4
Not stated in public reviews

Tysabri

natalizumab · α4-integrin
Not stated in public reviews

Tzield

teplizumab · CD3
Not stated in public reviews

Ultomiris

ravulizumab · Complement C5
Not stated in public reviews

Unituxin

dinutuximab · GD2
Not stated in public reviews

Unloxcyt

cosibelimab · PD-L1
Not stated in public reviews

Uplizna

inebilizumab · CD19
Not stated in public reviews

Vectibix

panitumumab · EGFR
Not stated in public reviews

Veopoz

pozelimab · Complement C5
Not stated in public reviews

Voyxact

sibeprenlimab · APRIL
Not stated in public reviews

Vyepti

eptinezumab · CGRP
Not stated in public reviews

Vyloy

zolbetuximab · Claudin 18.2
Not stated in public reviews

Xolair

omalizumab · IgE
Not stated in public reviews

Yartemlea

narsoplimab · MASP-2
Not stated in public reviews

Yervoy

ipilimumab · CTLA-4
Not stated in public reviews

Zinbryta

daclizumab · IL-2Rα (CD25)
Not stated in public reviews

Zinplava

bezlotoxumab · C. difficile toxin B
Not stated in public reviews

Zynyz

retifanlimab · PD-1
Not stated in public reviews

Summary across all 117 monoclonal antibodies →